Cargando…
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndrome and on Dialysis: A Meta-Analysis
This study aims to compare the safety and efficacy of clopidogrel and ticagrelor in patients with acute coronary syndrome (ACS) and undergoing dialysis. This study was conducted per the guidelines of the Preferred Reporting of Systematic Reviews and Meta-Analyses (PRISMA). A comprehensive search was...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332118/ https://www.ncbi.nlm.nih.gov/pubmed/37435247 http://dx.doi.org/10.7759/cureus.40211 |
_version_ | 1785070379806490624 |
---|---|
author | Chenna, Venkata Sai Harshabhargav Anam, Hemalatha Hassan, Majid Moeez, Abdul Reddy, Raja Chaudhari, Sandipkumar S Sapkota, Koushik Usama, Muhammad |
author_facet | Chenna, Venkata Sai Harshabhargav Anam, Hemalatha Hassan, Majid Moeez, Abdul Reddy, Raja Chaudhari, Sandipkumar S Sapkota, Koushik Usama, Muhammad |
author_sort | Chenna, Venkata Sai Harshabhargav |
collection | PubMed |
description | This study aims to compare the safety and efficacy of clopidogrel and ticagrelor in patients with acute coronary syndrome (ACS) and undergoing dialysis. This study was conducted per the guidelines of the Preferred Reporting of Systematic Reviews and Meta-Analyses (PRISMA). A comprehensive search was performed using electronic databases, including PubMed, EMBASE, and Web of Science, to identify relevant studies comparing clopidogrel and ticagrelor in patients undergoing dialysis. To ensure the inclusion of all relevant articles, a combination of the following keywords, along with medical subject heading (MeSH) terms, was used: "clopidogrel," "ticagrelor," "acute coronary syndrome," and "dialysis." The primary endpoint of this meta-analysis was the incidence of major adverse cardiovascular events (MACE), which consisted of cardiovascular death, myocardial infarction, stroke, and revascularization. The secondary endpoint was all-cause mortality. The occurrence of any bleeding events (including major and nonmajor bleeding events) and major bleeding events was chosen as the safety endpoints. A total of four studies were included in the pooled analysis. The pooled sample size was 5,417 patients, including 892 in the ticagrelor group and 4525 in the clopidogrel group. The findings indicate that ticagrelor, compared to clopidogrel, is associated with a significantly higher risk of MACEs, all-cause death, and major bleeding events. The findings suggest that clopidogrel may be a better choice for individuals with ACS undergoing dialysis due to its lower risk of MACE, all-cause death, and major bleeding events compared to ticagrelor. |
format | Online Article Text |
id | pubmed-10332118 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-103321182023-07-11 Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndrome and on Dialysis: A Meta-Analysis Chenna, Venkata Sai Harshabhargav Anam, Hemalatha Hassan, Majid Moeez, Abdul Reddy, Raja Chaudhari, Sandipkumar S Sapkota, Koushik Usama, Muhammad Cureus Cardiology This study aims to compare the safety and efficacy of clopidogrel and ticagrelor in patients with acute coronary syndrome (ACS) and undergoing dialysis. This study was conducted per the guidelines of the Preferred Reporting of Systematic Reviews and Meta-Analyses (PRISMA). A comprehensive search was performed using electronic databases, including PubMed, EMBASE, and Web of Science, to identify relevant studies comparing clopidogrel and ticagrelor in patients undergoing dialysis. To ensure the inclusion of all relevant articles, a combination of the following keywords, along with medical subject heading (MeSH) terms, was used: "clopidogrel," "ticagrelor," "acute coronary syndrome," and "dialysis." The primary endpoint of this meta-analysis was the incidence of major adverse cardiovascular events (MACE), which consisted of cardiovascular death, myocardial infarction, stroke, and revascularization. The secondary endpoint was all-cause mortality. The occurrence of any bleeding events (including major and nonmajor bleeding events) and major bleeding events was chosen as the safety endpoints. A total of four studies were included in the pooled analysis. The pooled sample size was 5,417 patients, including 892 in the ticagrelor group and 4525 in the clopidogrel group. The findings indicate that ticagrelor, compared to clopidogrel, is associated with a significantly higher risk of MACEs, all-cause death, and major bleeding events. The findings suggest that clopidogrel may be a better choice for individuals with ACS undergoing dialysis due to its lower risk of MACE, all-cause death, and major bleeding events compared to ticagrelor. Cureus 2023-06-10 /pmc/articles/PMC10332118/ /pubmed/37435247 http://dx.doi.org/10.7759/cureus.40211 Text en Copyright © 2023, Chenna et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Cardiology Chenna, Venkata Sai Harshabhargav Anam, Hemalatha Hassan, Majid Moeez, Abdul Reddy, Raja Chaudhari, Sandipkumar S Sapkota, Koushik Usama, Muhammad Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndrome and on Dialysis: A Meta-Analysis |
title | Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndrome and on Dialysis: A Meta-Analysis |
title_full | Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndrome and on Dialysis: A Meta-Analysis |
title_fullStr | Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndrome and on Dialysis: A Meta-Analysis |
title_full_unstemmed | Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndrome and on Dialysis: A Meta-Analysis |
title_short | Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndrome and on Dialysis: A Meta-Analysis |
title_sort | ticagrelor versus clopidogrel in patients with acute coronary syndrome and on dialysis: a meta-analysis |
topic | Cardiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332118/ https://www.ncbi.nlm.nih.gov/pubmed/37435247 http://dx.doi.org/10.7759/cureus.40211 |
work_keys_str_mv | AT chennavenkatasaiharshabhargav ticagrelorversusclopidogrelinpatientswithacutecoronarysyndromeandondialysisametaanalysis AT anamhemalatha ticagrelorversusclopidogrelinpatientswithacutecoronarysyndromeandondialysisametaanalysis AT hassanmajid ticagrelorversusclopidogrelinpatientswithacutecoronarysyndromeandondialysisametaanalysis AT moeezabdul ticagrelorversusclopidogrelinpatientswithacutecoronarysyndromeandondialysisametaanalysis AT reddyraja ticagrelorversusclopidogrelinpatientswithacutecoronarysyndromeandondialysisametaanalysis AT chaudharisandipkumars ticagrelorversusclopidogrelinpatientswithacutecoronarysyndromeandondialysisametaanalysis AT sapkotakoushik ticagrelorversusclopidogrelinpatientswithacutecoronarysyndromeandondialysisametaanalysis AT usamamuhammad ticagrelorversusclopidogrelinpatientswithacutecoronarysyndromeandondialysisametaanalysis |